Live tape
Top 8, mentions 7d9,857TSLA2,037 mentions▲ +0.05GOOGL1,585 mentions▲ +0.04NVDA1,207 mentions▲ +0.07CRWV1,197 mentions▲ +0.03SPCX1,070 mentions▲ +0.07QQQ1,042 mentions▲ +0.04META874 mentions▲ +0.05NBIS845 mentions▲ +0.05

Equity · Healthcare

MYGN

NASDAQ

Myriad Genetics, Inc.

$6.18 −0.48% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close)
Price · Chart

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for MYGN to draw a line in its place.

Track this symbol on TradingView TradingView chart
Market cap $591.1M
52-week range $3.54 – $8.10
Avg volume 376.0K

as of Jul 17, 2026

MYGN insider trades

SEC Form 4 · last 90 days · newest Form 4 filing 21 Sep 2026
Open-market buys 0
Open-market sells 0
Non-trade filings 4

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
21 Sep 2026 Wheeler Benjamin Richard Chief Financial Officer Tax withheld 2,555 $10K
16 Sep 2026 Sikri Vishal EVP, Commercial Award 257,731
03 Sep 2026 Fox Jennifer Lynne Chief Legal Officer Tax withheld 4,398 $14K
16 Aug 2026 Wheeler Benjamin Richard Chief Financial Officer Tax withheld 8,761 $27K

MYGN reported financials

SEC EDGAR XBRL SEC EDGAR

MYGN reported revenue of $824.5M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$365.9M.

Figure Reported Period
Revenue $824.5M 31 Dec 2025 fiscal year
Net income −$365.9M 31 Dec 2025 fiscal year
Diluted EPS −$3.95 31 Dec 2025 fiscal year
Total assets $638.9M 30 Jun 2026 at period end
Total equity $303.9M 30 Jun 2026 at period end

MYGN earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 −$0.46 —
31 Mar 2026 Q1 2026 −$0.36 —
31 Dec 2025 FY 2025 −$3.95 —
30 Sep 2025 Q3 2025 −$0.29 —
30 Jun 2025 Q2 2025 −$3.57 —
31 Mar 2025 Q1 2025 $0.00 —
31 Dec 2024 FY 2024 −$1.41 —
30 Sep 2024 Q3 2024 −$0.24 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

MYGN institutional holders

SEC Form 13F SEC EDGAR

10 of the 45 institutional funds we track reported a MYGN position for the quarter ended 30 Jun 2026 — a combined $111.4M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Millennium Management Held (±25%) −0.7% shares 6,620,372 $37.8M
D. E. Shaw & Co. Held (±25%) +1.8% shares 4,582,083 $26.2M
AQR Capital Management Added +44.7% shares 2,766,689 $15.8M
Two Sigma Investments Held (±25%) +21.3% shares 1,557,727 $8.9M
Citadel Advisors Added +238.5% shares 1,533,684 $8.8M
Marshall Wace Held (±25%) +10.8% shares 1,222,804 $7.0M
Man Group Added +226.6% shares 908,733 $5.2M
Point72 Asset Management Trimmed −75.1% shares 238,776 $1.4M
Tudor Investment Corp Held (±25%) −1.8% shares 44,680 $255K
Balyasny Asset Management New position 36,860 $210K

MYGN fails-to-deliver

SEC CNS data SEC

On 22 Sep 2026, 10,635 shares of MYGN failed to deliver (about $43K).

Settlement date Shares failed Notional % of shares out
22 Sep 2026 10,635 $43K 0.011%
10 Sep 2026 682 $2K 0.001%

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARValuation computed from SEC EDGAR filings